LivaNova (NASDAQ:LIVN) Stock Passes Below Fifty Day Moving Average of $57.89

LivaNova PLC (NASDAQ:LIVN) shares crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $57.89 and traded as low as $52.75. LivaNova shares last traded at $52.89, with a volume of 546,551 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Robert W. Baird increased their price objective on LivaNova from $58.00 to $66.00 and gave the stock a “neutral” rating in a research report on Thursday, May 2nd. StockNews.com raised shares of LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Needham & Company LLC reiterated a “buy” rating and set a $72.00 target price on shares of LivaNova in a research report on Thursday, June 6th. Finally, Mizuho increased their price target on shares of LivaNova from $75.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, LivaNova currently has an average rating of “Moderate Buy” and a consensus price target of $66.20.

LivaNova Price Performance

The stock has a market capitalization of $2.86 billion, a PE ratio of -87.98 and a beta of 0.99. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.17 and a quick ratio of 2.71. The firm’s 50 day simple moving average is $57.83 and its 200 day simple moving average is $54.24.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.28. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The firm had revenue of $294.90 million for the quarter, compared to analysts’ expectations of $278.17 million. During the same period last year, the firm earned $0.43 earnings per share. The company’s revenue for the quarter was up 12.0% compared to the same quarter last year. As a group, equities analysts forecast that LivaNova PLC will post 2.6 EPS for the current fiscal year.

Insider Activity

In related news, Director Daniel Jeffrey Moore sold 56,623 shares of LivaNova stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $60.11, for a total value of $3,403,608.53. Following the transaction, the director now directly owns 27,534 shares of the company’s stock, valued at $1,655,068.74. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On LivaNova

Institutional investors and hedge funds have recently modified their holdings of the stock. Lazard Asset Management LLC purchased a new stake in LivaNova during the 1st quarter valued at about $84,000. Acadian Asset Management LLC purchased a new stake in LivaNova in the first quarter worth approximately $94,000. Headlands Technologies LLC raised its stake in LivaNova by 33.3% during the 4th quarter. Headlands Technologies LLC now owns 1,807 shares of the company’s stock valued at $93,000 after buying an additional 451 shares during the last quarter. Teza Capital Management LLC bought a new stake in shares of LivaNova in the third quarter worth $275,000. Finally, Entropy Technologies LP bought a new stake in shares of LivaNova during the 1st quarter valued at about $295,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.